Arthritis, Juvenile Idiopathic
9
1
1
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
33%
3 trials in Phase 3/4
83%
5 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
Pain in Inflammatory Joint Diseases
Hypnotherapy for Needle-related Procedural Pain and Anxiety Management in a Pediatric Setting
A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA
Start Time Optimization of Biologics in Polyarticular JIA
Juvenile Arthritis Quantitative Imaging
An Internet-based Self-management Program for Adolescents With Arthritis
Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)